Navigation Links
Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact
Date:10/29/2010

CHICAGO, Oct. 29 /PRNewswire-USNewswire/ -- New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual household incomes below $30,000 than those with episodic migraine (headache on < 15 days per month).  This difference in household income may be attributable to the greater adverse headache impact in the chronic migraine group.  Chronic migraine, a condition characterized by headaches more days than not, afflicts about 1 in 50 Americans.  This research is from the American Migraine Prevalence and Prevention Study (AMPP), the largest-ever longitudinal study of headache.

The study involved 373 individuals with chronic migraine and 6,554 with episodic migraine. Those with chronic migraine were more likely to have average annual household incomes below $30,000 than those with episodic migraine (38.3% of chronic migraineurs and 26.5% of episodic migraineurs had household incomes of less than $30,000/year).   The Headache Impact Test (HIT-6) measures the burden of headache in areas including work, school, social life, and feelings such as fatigue, irritability and difficulty with concentration over the previous month.  Those with chronic migraine had an average score of 64 (indicating "severe impact") and those with episodic migraine had an average score of 58 (indicating "substantial impact").

Study co-investigator, Dawn C. Buse, PhD,  Assistant Professor of Neurology at the Albert Einstein College of Medicine and Director of Behavioral Medicine at the Montefiore Headache Center, Bronx, NY, said,  "These results reinforce the fact that the impact of headache is most significant among persons with chronic migraine when compared to persons with episodic migraine.  In addition, we find that headache impact is predicted by headache pain intensity, severity of associated symptoms, and the presence of depression."

The good news according to study co-investigator, Richard B. Lipton, MD, Professor of Neurology at Einstein and Director of the Montefiore Headache Center, is that chronic migraine, its symptoms, and comorbidities including depression and anxiety are very treatable.  Dr. Lipton advises, "Persons living with chronic migraine should speak with a knowledgeable health care professional about available treatments."

Background

The American Migraine Prevalence and Prevention study began in 2004 when questionnaires were mailed to 120,000 U.S. households to identify severe headache sufferers.  A sample of 24,000 severe headache sufferers, identified in 2004, have been followed annually through 2009.  The 2009 survey included the Headache Impact Test (HIT-6), a self administered, six-item questionnaire that measures pain severity, activity limitations, fatigue, irritability and difficulty concentrating due to headache.  Total sum scores range from 36-78 in the following categories: "no/little impact" (<50), "some impact" (50-55), "substantial impact" (56-59), and "severe impact" (60+).

Migraine is a neurological syndrome characterized by severe, painful headaches that are often accompanied by nausea, vomiting, and increased sensitivity to light and sound.  Headaches may last for hours or even days.  The pain is often on one side of the head and pulsating.  Headaches may be preceded by aura: sensory warning signs such as flashes of light, blind spots, tingling in the arms and legs.  

Migraine can place a significant burden on headache sufferers, their families, and society.   And chronic migraine has been demonstrated to have even greater impact than episodic migraine on a range of factors including socioeconomic status (employment status, household income), headache-related-disability (missed time from work, family and leisure activities), health-related quality of life, and direct and indirect medical costs.  It has also been established that those with chronic migraine are more likely to have additional comorbid medical and psychiatric conditions.

Sponsorship: The American Migraine Prevalence and Prevention Study is funded through a research grant to the National Headache Foundation from Ortho-McNeil Neurologics, Inc., Titusville, NJ.  Additional analyses for this work were supported by Allergan Inc., Irvine, CA.

To learn more about severe headaches, visit the National Headache Foundation website at www.headaches.org, or find a headache specialist in your area.


'/>"/>
SOURCE National Headache Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... Horizon Goodwill Industries, SourceAmerica and ... high school girls succeed in STEM programs as well as help Horizon Goodwill ... over 20 high school girls at their corporate headquarters on Tuesday, July 25, ...
(Date:7/24/2017)... ... 2017 , ... The International Essential Tremor Foundation (IETF) will host a free ... The seminar will take place on Saturday, Aug. 26 at the Embassy Suites by ... run from 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. The ...
(Date:7/24/2017)... NY (PRWEB) , ... July 24, 2017 , ... ... series of media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn ... elements is one of the leading causes of long term skin conditions, including ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally ... on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an ... China. , The article by Zidor Aldama described the situation in which Chinese children ...
Breaking Medicine News(10 mins):